Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.40 |
| ▸ | FAP | Q12884 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1445688 | 1.00 | DPP4 (0.41) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL353690 | 1.00 | DPP4 (0.41) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL5706355 | 0.98 | DPP4 (0.40) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL5079153 | 0.98 | DPP4 (0.40) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL27529254 | 0.98 | DPP4 (0.40) | DPP4DPP8DPP9DPP7FAP | |
| Fumaric Acid SCHEMBL4955812 | 0.92 | DPP4 (0.36) | DPP4DPP8DPP9DPP7FAP | |
| Fumaric Acid SCHEMBL4948911 | 0.92 | DPP4 (0.36) | DPP4DPP8DPP9DPP7FAP | |
| Fumaric Acid SCHEMBL27529255 | 0.92 | DPP4 (0.36) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL27755779 | 0.87 | DPP4 (0.49) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7056083 | 0.84 | DPP4 (0.35) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 463 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927504-B2 | Combined use of dipeptidyl peptidase 4 inhibitor and sweetener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-01-06 | — | — | US | claimed |
| EP-2055302-B1 | Method for the improvement of islet signaling in diabetes mellitus and for its prevention | ROYALTY PHARMA COLLECTION TRUST (US) | 2014-09-10 | — | — | EP | claimed |
| EP-1675578-B9 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2014-06-25 | — | — | EP | claimed |
| US-8470781-B2 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2013-06-25 | — | — | US | claimed |
| EP-1675578-B1 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2013-05-22 | — | — | EP | claimed |
| EP-1283735-B2 | METHOD FOR THE IMPROVEMENT OF ISLET SIGNALING IN DIABETES MELLITUS AND FOR ITS PREVENTION | ROYALTY PHARMA COLLECTION TRUST (US) | 2012-10-24 | — | — | EP | claimed |
| US-8168199-B2 | Dipeptidyl peptidase IV inhibitors for the treatment of schizophrenia and depression | von Hoersten, Stephan (DE) | 2012-05-01 | — | — | US | claimed |
| EP-1713780-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-01-18 | — | — | EP | claimed |
| JP-4806628-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| EP-2338490-A2 | Combinations Useful for the Treatment of Neuronal Disorders | Probiodrug AG (DE) | 2011-06-29 | — | — | EP | claimed |
| US-20030130199-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG (DE) | 2003-07-10 | — | — | US | claimed |
| US-20030119750-A1 | Use of dipeptidyl peptidase IV inhibitors | PROBIODRUG (DE) | 2003-06-26 | — | — | US | claimed |
| EP-1082314-B1 | NEW DIPEPTIDYL PEPTIDASE IV EFFECTORS | PROBIODRUG AG (DE) | 2003-04-23 | — | — | EP | claimed |
| US-6548481-B1 | Effectors of dipeptidyl peptidase IV | PROBIODRUG AG (DE) | 2003-04-15 | — | — | US | claimed |
| EP-1292300-A1 | COMBINATIONS OD DIPEPTIDYL PEPTIDASE IV INHIBITORS AND OTHER ANTIDIABETIC AGENTS FOR THE TREATMENT FO DIABETE MELLITUS | SMITHKLINE BEECHAM PLC (GB) | 2003-03-19 | — | — | EP | claimed |
| US-20030008905-A1 | Increasing the capacity of insulin providing cells in an animal by administering to animal a dose of at least one Dipeptidyl-peptidase (DP IV) enzyme activity effector | PROSIDION LIMITED (GB) | 2003-01-09 | — | — | US | claimed |
| US-6500804-B2 | ADMINISTERING A DIPEPTIDYL AMINOPEPTIDASE EFFECTOR WHICH IS SELECTED FROM THE GROUP CONSISTING OF N-(N-SUBSTITUTED GLYCYL)2-CYANOPYRROLIDONES, N-AMINOACYL THIAZOLIDINES, N-AMINOACYL PYRROLIDINES | PROBIODRUG AG (DE) | 2002-12-31 | — | — | US | claimed |
| US-20020198242-A1 | Administering to an animal an effective dose of atleast an enzyme Dipeptidyl Peptidase (DP IV) enzyme activity effector to increase the capacity of insulin producing cells | PROSIDION LIMITED (GB) | 2002-12-26 | — | — | US | claimed |
| WO-2001097808-A1 | COMBINATIONS OF DEPEPTIDYL PEPTIDASE IV INHIBITORS AND OTHER ANTIDIABETIC AGENTS FOR THE TREATMENT OF DIABETE MELLITUS | SMITHKLINE BEECHAM PLC (GB) | 2001-12-27 | — | — | WO | claimed |
| US-20010051646-A1 | Administering a dipeptidyl aminopeptidase effector which is selected from the group consisting of N-(N-substituted glycyl)2-cyanopyrrolidones, N-aminoacyl thiazolidines, N-aminoacyl pyrrolidines | PROSIDION LIMITED (GB) | 2001-12-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130199-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | DPP4, DPP3, DNPEP | DPP4 1/4885DPP8 6/4885DPP9 5/4885 |
| US-20030119750-A1 | Use of dipeptidyl peptidase IV inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 6/4885DPP9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.